Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Lancet (London, England)|December 16, 2017
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trialMichael Wang, Simon Rule, Pier Luigi Zinzani, et al.
Haematologica|November 12, 2020
A prognostic index predicting survival in transformed Waldenström macroglobulinemiaEric Durot, Lukshe Kanagaratnam, Saurabh Zanwar, et al.
Blood|February 18, 2021
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemiaCharles Herbaux, Christoph Kornauth, Stéphanie Poulain, et al.
The Lancet. Haematology|May 25, 2024
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 studyJehan Dupuis, Emmanuel Bachy, Franck Morschhauser, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2024
Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohortAmélie Anota, Mathurine Basset, Emilie Charton, et al.
The Lancet. Oncology|January 20, 2019
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 studyRené-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, et al.
American Journal of Hematology|October 15, 2013
Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup studyLiesbeth C de Wreede, Maggie Watson, Marleen van Os, et al.
Blood|November 21, 2024
Inflammatory Waldenström macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohortPierre-Edouard Debureaux, Stéphanie Poulain, Stéphanie Harel, et al.
Haematologica|January 18, 2015
Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic LeukemiaCarol Moreno, Marco Montillo, Panayiotis Panayiotidis, et al.
Blood Cancer Journal|May 29, 2020
Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-upJerome Paillassa, Edouard Cornet, Stephanie Noel, et al.
Pageof 9